| Species |
Human |
| Protein Construction |
TACI/TNFRSF13B (Ser2-Thr166)_x000D_
Accession # O14836-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human BAFF Trimer, His Tag at 2μg/ml (100μl/well) on the plate can bind TACI/TNFRSF13B hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
45.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-40 kDa and 50-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) is one of the receptors of B cell activating factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL). TACI is a regulator in the immune responses. TACI inhibits B cell expansion and promotes the differentiation and survival of plasma cells. |
| Synonyms |
CD267; TNFRSF13B; TACI; CVID; CVID2; IGAD2; RYZN; TACI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
